Affordable Access

Publisher Website

Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B

Authors
Journal
British Journal of Cancer
0007-0920
Publisher
Nature Publishing Group
Publication Date
Identifiers
DOI: 10.1038/sj.bjc.6601460
Keywords
  • Clinical
Disciplines
  • Medicine

Abstract

Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B G Todeschini*,1, S Secchi1, E Morra2, U Vitolo3, E Orlandi4, F Pasini5, E Gallo3, A Ambrosetti1, C Tecchio1, C Tarella6, A Gabbas7, A Gallamini8,9, L Gargantini2, M Pizzuti10, G Fioritoni10, L Gottin11, G Rossi12, M Lazzarino4, F Menestrina13, M Paulli14, M Palestro15, MG Cabras16, F Di Vito17 and G Pizzolo1 1Department of Hematology, Verona University, Italy; 2Department of Hematology, Ospedale Niguarda, Milano, Italy; 3Department of Hematology, Ospedale S. Giovanni Battista, Torino, Italy; 4Department of Hematology, Pavia University, Italy; 5Department of Oncology, Verona University, Italy; 6Department of Hematology, Torino University, Italy; 7Department of Hematology, Ospedale S. Francesco, Nuoro, Italy; 8Department of Hematology, Ospedale Santa Croce, Cuneo, Italy; 9Department of Hematology, Ospedale S. Carlo, Potenza, Italy; 10Department of Hematology, Ospedale Santo Spirito, Pescara, Italy; 11Anesthesiology and Intensive Care Institute, Verona University, Italy; 12Department of Hematology, Spedali Riuniti, Brescia, Italy; 13Department of Pathology, Verona University, Italy; 14Department of Pathology, Pavia University, Italy; 15Department of Pathology, Torino University, Italy; 16Department of Hematology, Ospedale Businco, Cagliari, Italy; 17Department of Oncology, Ospedale Regionale, Aosta, Italy The optimal treatment of primary mediastinal large B-cell lymphoma (PMLBCL) is still undefined. In the absence of randomised studies, we retrospectively analysed: (a) the effectiveness of two chemotherapy regimens (CHOP vs MACOP-B/VACOP-B) in complete remission (CR) achievement and event-free survival (EFS) and (b) the role of mediastinal involved-field radiotherapy (IF- RT) as consolidation. From 1982 to 1999, 138 consecutive patients affected by PMLBCL were treated in 13 Italian institutions with CHOP (43) or MACOP-B

There are no comments yet on this publication. Be the first to share your thoughts.